-Project NextGen Collaboration will Support Capricor's StealthX™ Exosome Platform and Provide Non-Dilutive Support for Advancement into the Clinic- SAN DIEGO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases, today announced that Capricor's proprietary StealthX™ exosome-based multivalent vaccine (StealthX™ vaccine) for the prevention of SARS-CoV-2 has ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2023 Results Conference Call November 14, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen and welcome to the Capricor’s Third Quarter 2023 Financial Results and Corporate Update Call. This conference call is being recorded. I would now like to turn the conference call over to our host, Mr. AJ Bergmann, Cap ...

| --- | --- | --- | --- | --- | |---------------------------------------------------------------------------------|-------|------------------------------------|-------|-----------------------| | CURRENT ASSETS | | September 30, 2023 (unaudited) | | December 31, 2022 | | Cash and cash equivalents | $ | 8,984,667 | $ | 9,603,242 | | Marketable securities | | 19,536,805 | | 31,818,020 | | Receivables | | 547,580 | | 547,580 | | Prepaid expenses and other current assets | | 458,417 | | 919,892 | | | | | | | | T ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q2 2023 Earnings Call Transcript August 7, 2023 4:20 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Operator Good afternoon, ladies and gentlemen and welcome to the Capricor Therapeutics Second Quarter 2023 Financial Results and Corporate Update Call. At this time all lines are in a listen-only mode. Following the presentation we’ll conduct a question-and-answer session. [Operator Instruct ...

Leases will be classified as financing or operating, which will drive the expense recognition pattern. The Company elects to exclude short-term leases if and when the Company has them. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which the Company could 38 For real estate leases, the Company has elected the practical expedient under ASC 842 to account for the lease and n ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Aydin Huseynov - Ladenburg Operator Good afternoon, ladies and gentlemen, this is the conference operator. Welcome to Capricor First Quarter 2023 Financial Results and Corporate Update Call. After the presentation there will be an opportunity to ask questions. [Operator Instructions] As a reminder, this conference is being ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☒ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2023 ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from to CAPRICOR THERAPEUTICS, INC. (Exact Name Of Registrant As Specified In Its Charter) 10865 Road to the Cure, Suite 150, San Diego, California 92121 (Address of principal executive o ...

groups once patients began treatment in the OLE. CAP-1002 treatment during the OLE portion of the study continues to yield a consistent safety profile and has been well-tolerated throughout the study. ● Exosome-Based Therapeutics and Vaccines (Preclinical): We are focused on developing a precisionengineered exosome platform technology that has the ability to deliver defined sets of effector molecules which exert their effects through defined mechanisms of action. We recently presented new preclinical data o ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q4 2022 Earnings Conference Call March 15, 2023 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - CEO Conference Call Participants Joseph Pantginis - H.C. Wainwright Michael Okunewitch - Maxim Group Aydin Huseynov - Ladenburg Brian Corday - BullBear Partners Operator Good afternoon, and welcome to Capricor Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode. A brief qu ...

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - CEO Conference Call Participants Alan Leong - BioWatch News Aydin Huseynov - Ladenburg Brian Corday - BullBear Partners Operator Good day, ladies and gentlemen, and welcome to the Capricor Therapeutics Incorporated Third Quarter 2022 Earnings Call. Today's conference is being recorded. At this time, I'd like to turn the conference over to Mr. AJ Bergman ...